Phase 2 RCT in 61 treated patients with multiple system atrophy: amlenetug vs placebo did not meet the primary endpoint (89.4% probability of slowing progression vs 97.5% threshold; non-significant 19% slowing); serious adverse events 30% vs 33%.
RCTn = 64
Kjærsgaard et al. Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial